The Fall ACS virtual convention was held August 17 – August 20, 2020. In case you’re interested, there were many talks in the AGRO section including talks related to Hemp and pesticides. There was a presentation by EPA and also IR-4.
University of California’s publication on Herbicide Damage Symptoms and Hemp
Transcripts of Senate Hearings on Hemp:
Colorado Department of Agriculture and Colorado Department of Public Health & Environment, Joint Letter to FDA: Comments on Scientific Data and Information About Products Containing Cannabis or Cannabis-Derived Compounds
Docket: FDA’s Request for Comments (due July 16, 2019): Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds: Public Hearing
Department of Health and Human Services June 7, 2019 Memo and Links to Webinars (you will need to copy and paste the links to the session you are interested in, and have adobe connect to view the webinar):
June 7, 2019
On behalf of the U.S. Food and Drug Administration (FDA), the Office of External Affairs, Stakeholder Engagement Staff, thanks you for your participation at the FDA’s Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds Public Hearing held on Friday, May 31, 2019. Your participation was essential to enhance our awareness of the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds.
Opening remarks by Norman E. “Ned” Sharpless MD, Acting Commissioner of Food and Drugs, are available at:https://www.fda.gov/news-events/speeches-fda-officials/remarks-dr-sharpless-fda-public-hearing-scientific-data-and-information-about-products-containing.
A recording of the entire hearing is available in four distinct segments. Each segment is in order based on the hearing’s agenda. Event materials are available at: https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/scientific-data-and-information-about-products-containing-cannabis-or-cannabis-derived-compounds.
- Segment 1https://collaboration.fda.gov/pr8clhusaf72/(opening until morning break)
- Segment 2https://collaboration.fda.gov/p69wh5mase6j/(after morning break until lunch)
- Segment 3https://collaboration.fda.gov/plubcsivwhe6/(after lunch until afternoon break)
- Segment 4https://collaboration.fda.gov/pihtiz8flmf7/(after afternoon break until closing)
We plan to publish the hearing transcript and slide decks in approximately 30 days athttps://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/scientific-data-and-information-about-products-containing-cannabis-or-cannabis-derived-compounds.
Please remember to submit your comments and supporting data to the docket atFDA-2019-N-1482by 11:59 p.m. (ET), Tuesday, July 2, 2019.
Again, thank you for your interest related to products containing cannabis or cannabis-derived compounds and we look forward to your continued participation on this topic.
Stakeholder Engagement Staff
Office of External Affairs
U.S. Food and Drug Administration
Oregon Governor Brown’s statement regarding the DOJ memo, January 2018
OMRI Response to Oregon’s Pesticide Advisory, November 2017
Oregon issues 5 SSURO’s for adulterated products used on cannabis, August 2017:
Special Local Need registrations for pesticides
State Specific Cannabis information and websites